- Home
- FDBC vs AVIR Comparison
FDBC vs AVIR Comparison
Compare FDBC & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDBC
- AVIR
- Stock Information
- Founded
- FDBC 1902
- AVIR 2012
- Country
- FDBC United States
- AVIR United States
- Employees
- FDBC N/A
- AVIR N/A
- Industry
- FDBC Major Banks
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- FDBC Finance
- AVIR Health Care
- Exchange
- FDBC Nasdaq
- AVIR Nasdaq
- Market Cap
- FDBC 234.2M
- AVIR 277.8M
- IPO Year
- FDBC N/A
- AVIR 2020
- Fundamental
- Price
- FDBC $40.88
- AVIR $3.50
- Analyst Decision
- FDBC
- AVIR Hold
- Analyst Count
- FDBC 0
- AVIR 1
- Target Price
- FDBC N/A
- AVIR $6.00
- AVG Volume (30 Days)
- FDBC 8.1K
- AVIR 361.0K
- Earning Date
- FDBC 07-23-2025
- AVIR 08-07-2025
- Dividend Yield
- FDBC 3.91%
- AVIR N/A
- EPS Growth
- FDBC 49.33
- AVIR N/A
- EPS
- FDBC 4.10
- AVIR N/A
- Revenue
- FDBC $84,975,000.00
- AVIR N/A
- Revenue This Year
- FDBC N/A
- AVIR N/A
- Revenue Next Year
- FDBC N/A
- AVIR N/A
- P/E Ratio
- FDBC $9.97
- AVIR N/A
- Revenue Growth
- FDBC 20.65
- AVIR N/A
- 52 Week Low
- FDBC $37.00
- AVIR $2.46
- 52 Week High
- FDBC $61.21
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- FDBC 43.99
- AVIR 48.71
- Support Level
- FDBC $39.36
- AVIR $3.33
- Resistance Level
- FDBC $43.13
- AVIR $3.60
- Average True Range (ATR)
- FDBC 0.88
- AVIR 0.16
- MACD
- FDBC 0.12
- AVIR -0.02
- Stochastic Oscillator
- FDBC 42.92
- AVIR 26.69
About FDBC Fidelity D & D Bancorp Inc.
Fidelity D & D Bancorp Inc is a bank holding company. Through its wholly-owned state-chartered commercial bank subsidiary, The Fidelity Deposit and Discount Bank (the Bank), it offers a full range of traditional banking services. The Bank has a personal and corporate trust department and also provides alternative financial and insurance products with asset management services. Its primary market areas are Lackawanna, Luzerne and Northampton Counties, Pennsylvania. The company's primary deposit products are demand deposits and interest-bearing time, money market and savings accounts. It offers a full array of loan products to meet the needs of retail and commercial customers. Company includes segments: Commercial and Industrial, Commercial Real Estate, Consumer, Residential Real Estate.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).